Imunon, Inc.
Imunon, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 5.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 10 concluded trials, 70% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 10, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 30, 2027 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Trial Milestone | Phase 1/Phase 2 |
| October 31, 2032 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | Trial Milestone | Phase 3 |
Track IMNN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IMNN in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.